Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report ) was the target of unusual options trading activity on Monday, as traders purchased 2,613 put options on the stock, an increase of roughly 148% compared to the typical daily trading volume of 1,055 put options.
Analyst Rating Changes
Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and a $12.00 price target on shares of Sana Biotechnology in a research note on Thursday, May 9th. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. The firm issued a “buy” rating and a $16.00 price target on the company. One research analyst has issued a hold rating to the stock, and four have issued a buy rating to the stock. According to MarketBeat data, Sana Biotechnology currently has an average rating of a “moderate buy” with an average price target of $12.75.
Read the latest research report on Sana Biotechnology
Sana Biotechnology’s Price Performance
NASDAQ:SANA traded at $6.13 in midday trading on Monday, up $0.33. The company’s stock was traded at 306,859 shares, compared to its average trading volume of 2,573,658 shares. Sana Biotechnology’s 52-week low is $2.74 and its 52-week high is $12.00. The company’s 50-day moving average is $6.68 and its 200-day moving average is $7.56.
Sana Biotechnology (NASDAQ:SANA – Get free report ) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). On average, sell-side analysts expect that Sana Biotechnology will post -1.15 EPS for the current fiscal year.
Institutional Investors Invest in Sana Biotechnology
Several hedge funds and other institutional investors have recently added to or reduced their holdings of Sana Biotechnology. The Vanguard Group increased its holdings in Sana Biotechnology by 1.2% in the third quarter. The Vanguard Group now owns 9,167,585 shares of the company’s stock, valued at $35,479,000, after acquiring an additional 107,167 shares during the period. SG Americas Securities acquired a new stake in Sana Biotechnology in the fourth quarter, valued at $99,000. China Universal Asset Management increased its holdings in Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management now owns 22,800 shares of the company’s stock, valued at $93,000, after acquiring an additional 17,753 shares during the last quarter. Arizona State Retirement System increased its holdings in Sana Biotechnology by 12.2% in the fourth quarter. Arizona State Retirement System now holds 27,527 shares, valued at $112,000, after purchasing an additional 2,991 shares during the period.Finally, Mirae Asset Global Investments Inc. increased its holdings in Sana Biotechnology by 286.4% in the fourth quarter. Mirae Asset Global Investments Inc. now holds 197,386 shares, valued at $805,000, after purchasing an additional 146,303 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.
Sana Biotechnology Company Profile
(Get your free report)
Sana Biotechnology, Inc. is a biotechnology company focused on the use of genetically engineered cells as medicines. The company is developing in vitro and in vivo cell engineering platforms for a variety of therapeutic areas of unmet therapeutic need, including oncology, diabetes, central nervous system disorders and B-cell mediated autoimmunity.
Recommended articles
Get Sana Biotechnology News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Sana Biotechnology and related companies every day with MarketBeat.com’s free email newsletter.
